Supriya Srinivasan

Supriya Srinivasan

Auto-generated profile, based on publicly available information

Supriya Srinivasan

Department of Surgery, University of Miami, Miller School of Medicine, Miami, Florida

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
SMSiddharth Mehra
Siddharth Mehra
VGVanessa T. Garrido
Vanessa T. Garrido
ADAustin Richard Dosch
Austin Richard Dosch
PLPurushottam Lamichhane
Purushottam Lamichhane
SSSupriya Srinivasan
Supriya Srinivasan
NNNagaraj Nagathihalli
Nagaraj Nagathihalli
Pancreatic ductal adenocarcinoma (PDAC) is a significant contributor to cancer-related morbidity and mortality, and it is known for its resistance to conventional treatment regimens, including chemotherapy and immune checkpoint blockade (ICB)-based therapies. We have previously shown that Urolithin A (Uro A), a gut microbial metabolite derived from pomegranates, can target and inhibit KRAS-dependent PI3K/AKT/mTOR signaling pathways to overcome therapeutic resistance and improve survival in PDAC. However, the effect of Uro A on the tumor immune microenvironment and its ability to enhance ICB efficacy has not been explored. This study demonstrates that Uro A treatment reduces stromal fibrosis and reinvigorates the adaptive T-cell immune response to overcome resistance to PD-1 blockade in a genetically engineered mouse model (GEMM) of PDAC. Flow cytometric–based analysis of Uro A-treated mouse tumors revealed a significant attenuation of immunosuppressive tumor-associated M2-like macrophages with a concurrent increase in the infiltration of CD4+ and CD8+ T cells with memory-like phenotype along with reduced expression of the exhaustion-associated protein, PD-1. Importantly, the combination of Uro A treatment with anti-PD-1 immunotherapy promoted enhancement of the antitumor response with increased infiltration of CD4+ Th1 cells, ultimately resulting in a remarkable improvement in overall survival in GEMM of PDAC. Overall, our findings provide preclinical evidence for the potential of Uro A as a novel therapeutic agent to increase sensitivity to immunotherapy in PDAC and warrant further mechanistic exploration in preclinical and clinical studies. Significance: Immunotherapeutic agents are ineffective against pancreatic cancer, mainly due to the immunosuppressive tumor microenvironment and stromal desmoplasia. Our current study demonstrates the therapeutic utility of a novel gut microbial metabolite, Uro A, to remodel the stromal-immune microenvironment and improve overall survival with anti-PD-1 therapy in pancreatic cancer.

12 July 2023
Verified
Other
Open access
PDF file
SMSiddharth Mehra
Siddharth Mehra
VGVanessa T. Garrido
Vanessa T. Garrido
ADAustin Richard Dosch
Austin Richard Dosch
PLPurushottam Lamichhane
Purushottam Lamichhane
SSSupriya Srinivasan
Supriya Srinivasan
NNNagaraj Nagathihalli
Nagaraj Nagathihalli
Tumor weight, mouse weight and cytokine profiling of Uro A treatment in PKT mice.

12 July 2023
Verified
Other
Open access
SMSiddharth Mehra
Siddharth Mehra
VGVanessa T. Garrido
Vanessa T. Garrido
ADAustin Richard Dosch
Austin Richard Dosch
PLPurushottam Lamichhane
Purushottam Lamichhane
SSSupriya Srinivasan
Supriya Srinivasan
NNNagaraj Nagathihalli
Nagaraj Nagathihalli
Uro A treatment downregulates PI3K/AKT/mTOR pathway, reduces primary tumor burden, alters the stromal composition and immunomodulatory profile of the TME in a spontaneous murine model of PDAC. A, mRNA levels of AKT1 in normal pancreatic tissue (Normal; n = 171) and patients with primary PDAC (Tumor; n = 179) from GTEx and pancreatic adenocarcinoma (PAAD) TCGA database. B, Representative H&E-stained pancreas sections and IHC imaging analysis demonstrating pAKT and pP70S6K expression in the pancreatic tissue sections of non–tumor-bearing Ptf1aCre, and tumor-bearing KPC and PKT GEMMs of PDAC. Quantification of relative areas of positive staining in (within the tumor area) tissue sections from vehicle, and Uro A-treated tumors are indicated in adjacent plots. C, Schematic of vehicle or Uro A (20 mg/kg/day) treatment in PKT mice. Treatment was initiated at 4.5 weeks of age when mice reproducibly developed palpable tumors and was continued for 3 weeks before sacrifice. D, Pancreas weight analysis of Uro A or vehicle-treated PKT mice. E, Western blot analysis showing decreased pAKT and pP70S6K in PKT mice pancreata after Uro A treatment as compared with vehicle-treated PKT mice, n = 3 mice/group. F, Representative H&E-stained tumor sections, and IHC imaging analysis demonstrating reduction in pAKT and pP70S6K expression within the ductal compartment of pancreatic tissue sections following Uro A treatment in PKT GEMM, n = 3 mice/group. G, Collagen 1, trichrome blue staining, and their corresponding quantification analysis in pancreatic tumor tissues harvested from PKT mice treated with Uro A or vehicle, n = 5 mice/group. H, Cytokine array profiling of pancreatic tumor tissues harvested from PKT mice treated with Uro A or vehicle. Scale bar = 50 μm. Individual datapoints with mean ± SEM are shown and compared by two-tailed unpaired t test for two group comparison and one-way ANOVA for multiple comparisons; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, P > 0.05.

12 July 2023
Verified
Other
Open access
SMSiddharth Mehra
Siddharth Mehra
VGVanessa T. Garrido
Vanessa T. Garrido
ADAustin Richard Dosch
Austin Richard Dosch
PLPurushottam Lamichhane
Purushottam Lamichhane
SSSupriya Srinivasan
Supriya Srinivasan
NNNagaraj Nagathihalli
Nagaraj Nagathihalli
Primary antibodies for flow cytometry, immunohistochemistry and Western blot analysis.

12 July 2023
Verified
Other
Open access
PDF file
SMSiddharth Mehra
Siddharth Mehra
VGVanessa T. Garrido
Vanessa T. Garrido
ADAustin Richard Dosch
Austin Richard Dosch
PLPurushottam Lamichhane
Purushottam Lamichhane
SSSupriya Srinivasan
Supriya Srinivasan
NNNagaraj Nagathihalli
Nagaraj Nagathihalli
PD-L1 expression in Uro A or PI3Ki treated KPC cells.

12 July 2023
Verified
Other
Open access
PDF file
SMSiddharth Mehra
Siddharth Mehra
VGVanessa T. Garrido
Vanessa T. Garrido
ADAustin Richard Dosch
Austin Richard Dosch
PLPurushottam Lamichhane
Purushottam Lamichhane
SSSupriya Srinivasan
Supriya Srinivasan
NNNagaraj Nagathihalli
Nagaraj Nagathihalli
Recorded body weights of PKT mice treated with Uro A, aPD-1 and Uro A+aPD-1.